Impel NeuroPharma has entered into service agreements with Camargo Pharmaceutical Services. Camargo will be providing end-to-end regulatory consulting and strategic development services for Impel’s pipeline of drug-device combination products built upon its Precision Olfactory Delivery (PODTM) nasal delivery platform. The first programs will concentrate on treatments for migraines and Alzheimer’s, including pre-investigational new drug (pre-IND) meeting planning and preparations through to new drug applications (NDA) submissions.

“Camargo has a deep experience in 505(b)(2) strategy and combination product development which perfectly complements Impel’s capabilities. Partnering with Camargo will allow Impel to take full advantage of our POD nasal drug delivery platform and efficiently develop multiple meaningful drug products,” said John Hoekman, chief executive officer, Impel NeuroPharma.

Ken Phelps, chief executive officer, Camargo Pharmaceutical Services, said, “By bringing together Camargo’s expertise with 505(b)(2) drug development and Impel Neuropharma’s revolutionary POD technology, we are able to help enable effective new therapies for patients worldwide. By utilizing the 505(b)(2) pathway and employing best strategies, Impel’s products will move through approval and reach the market in the most cost- and time-effective manner.”